EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fibrinolysis is impaired in patients with primary immune thrombocytopenia

Theresa Schramm, Jasmin Rast, Dino Mehic, Stéphanie E Reitsma, Claire de Moreuil, Michael Fillitz, Peter Quehenberger, Bas de Laat, Alisa S Wolberg, Cihan Ay, Ingrid Pabinger, Johanna Gebhart

Journal of Thrombosis and Haemostasis · 2024-11 · 22 (11) · 3209-3220

DOI: 10.1016/j.jtha.2024.07.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-11. Verfasst von Theresa Schramm und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Fibrinolysis, Purpura, Thrombocytopenic, Idiopathic, Plasminogen Activator Inhibitor 1, Tissue Plasminogen Activator. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stadt Wien.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with primary immune thrombocytopenia (ITP) have an increased risk of thrombosis, which may be due to altered fibrinolysis. OBJECTIVES: To elucidate the clinical impact of delayed fibrinolysis in ITP patients. METHODS: A turbidimetric clot formation and lysis assay and a fluorometric plasmin generation (PG) assay were performed, and levels of plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), tPA-PAI-1 complexes, α2-antiplasmin, thrombin activatable fibrinolysis inhibitor, and D-dimer were assessed in 86 adult primary ITP patients and 78 healthy controls (HCs). RESULTS: ITP patients showed significantly delayed clot formation, increased clot density, and prolonged clot lysis time (CLT) compared with HCs, with a median (IQR) CLT of 28.0 (13.7-34.7) minutes in patients and 17.3 (12.0-28.0) minutes in HCs, while in the PG assay, only the lag time was prolonged. In ITP patients compared with controls, PAI-1 was higher (1.2 [0.8-2.6] vs 1.1 [0.6-2.1] U/mL) and tPA antigen and activity were lower (tPA antigen: 2.6 [1.1-4.4] vs 3.7 [3.2-4.7] ng/mL; tPA activity ≤ 0 U/mL: 26% vs 7%). TPA-PAI-1 complex levels were positively associated with CLT in multiple linear regression analysis (β = 0.241; P = .019), whereas PG parameters were not associated with CLT. Six patients who developed thrombosis during follow-up had higher levels of tPA-PAI-1 complexes. CONCLUSION: Prolonged CLT and delayed onset of PG may indicate a hypofibrinolytic tendency in ITP patients, as also indicated by high PAI-1 and low tPA levels. No association was found between fibrinolytic potential and the bleeding phenotype, whereas higher tPA-PAI-1 complex levels were associated with prolonged CLT and increased in patients with future thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrinolysisPurpura, Thrombocytopenic, IdiopathicPlasminogen Activator Inhibitor 1Tissue Plasminogen ActivatorThrombosisHumansFemaleMaleMiddle AgedAdultCase-Control StudiesFibrin Fibrinogen Degradation ProductsAgedalpha-2-AntiplasminFibrin Clot Lysis TimeFibrinolysinCarboxypeptidase B2BiomarkersTime Factors

Stichwörter der Autor:innen

blood coagulation testsclot lysis timefibrinolysisimmune thrombocytopeniaplasmin generation

Substanzen

Plasminogen Activator Inhibitor 1Tissue Plasminogen ActivatorSERPINE1 protein, humanFibrin Fibrinogen Degradation Productsalpha-2-Antiplasminfibrin fragment DFibrinolysinCarboxypeptidase B2BiomarkersPLAT protein, human

Autor:innen und Institutionen

  • Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
  • Department of Pathology and Laboratory Medicine and University of North Carolina at Chapel Hill (UNC) Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Internal Medicine, Vascular Medicine and Pneumology Department, Brest University Hospital, Brest, France; Unité Mixte de Recherche (UMR) 1304, Groupe d'Etude de Thrombose de Bretagne Occidentale (GETBO), Institut Nation…
  • Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria.
  • Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Net…

Förderung

  • Stadt Wien

Zitieren

APA

Schramm, T., Rast, J., Mehic, D., Reitsma, S. E., de Moreuil, C., Fillitz, M., Quehenberger, P., de Laat, B., Wolberg, A. S., Ay, C., Pabinger, I., & Gebhart, J. (2024). Fibrinolysis is impaired in patients with primary immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 22(11), 3209-3220. https://doi.org/10.1016/j.jtha.2024.07.034

Vancouver

Schramm T, Rast J, Mehic D, Reitsma SE, de Moreuil C, Fillitz M, et al. Fibrinolysis is impaired in patients with primary immune thrombocytopenia. Journal of Thrombosis and Haemostasis. 2024;22(11):3209-3220. doi:10.1016/j.jtha.2024.07.034

BibTeX
@article{Schramm2024,
  author = {Schramm, Theresa and Rast, Jasmin and Mehic, Dino and Reitsma, Stéphanie E and de Moreuil, Claire and Fillitz, Michael and Quehenberger, Peter and de Laat, Bas and Wolberg, Alisa S and Ay, Cihan and Pabinger, Ingrid and Gebhart, Johanna},
  title = {Fibrinolysis is impaired in patients with primary immune thrombocytopenia},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  volume = {22},
  number = {11},
  pages = {3209--3220},
  doi = {10.1016/j.jtha.2024.07.034}
}
Kostenlos starten →